In this study, we found the combination therapy decreased the frequency of Tregs, and increased CD8+ T cells and CD4+ T cells at tumor sites, with increased levels of IL-12 and IFN-γ and decreased IL-10 and TGF-β1. This evidence concerns the gene IL10 and neoplasm.